+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin-induced muscle toxicity and susceptibility to malignant hyperthermia and other muscle diseases: a population-based case-control study including 1st and 2nd degree relatives



Statin-induced muscle toxicity and susceptibility to malignant hyperthermia and other muscle diseases: a population-based case-control study including 1st and 2nd degree relatives



European Journal of Clinical Pharmacology 71(1): 117-124



Case reports have suggested an association between susceptibility to malignant hyperthermia (MH) and other muscle diseases in subjects with statin-induced muscle toxicity. The aim of the study was to further scrutinize this association in a population-based case-control study including 1st and 2nd degree relatives. Spontaneously reported cases with muscle disorders associated with statin therapy until September 2006 were identified in the Swedish Adverse Drug Reaction Registry at the Medical Products Agency. For each case, ten population-based controls, matched on year of birth and gender, were randomly selected from the National Registry of Swedish Citizens. First and 2nd degree relatives to cases and controls were identified in the Swedish Multi-Generation Registry. ICD codes that could be associated with susceptibility to MH or other muscle diseases were chosen, and subjects were followed until December 2007 with regard to occurrence of selected ICD codes in the Swedish Registries for Cause of Death and Hospital Discharge Diagnoses, respectively. The chosen ICD codes were significantly overrepresented in case families compared with control families (RR 1.56; 95 % CI 1.15-2.10). The strongest associations were identified for a diagnosis of drug-induced or specified or unspecified myopathy (RR 52; 95 % CI 22-123) or a diagnosis of unspecified hyperthermia in combination with drug-induced or specified or unspecified myopathy (RR 30; 95 % CI 6-148). In contrast, a diagnosis of unspecified hyperthermia in the absence of drug-induced or specified or unspecified myopathy was significantly underrepresented among case families (RR 0.42; 95 % CI 0.23-0.76). In a case-control study including 1st and 2nd degree relatives, statin-induced muscle toxicity was significantly associated with a diagnosis of drug-induced or specified or unspecified myopathy and with a diagnosis of unspecified hyperthermia in combination with a diagnosis of drug-induced or specified or unspecified myopathy.

(PDF emailed within 0-6 h: $19.90)

Accession: 055911586

Download citation: RISBibTeXText

PMID: 25367069

DOI: 10.1007/s00228-014-1776-9


Related references

Muscle biopsy for diagnosis of malignant hyperthermia susceptibility in two patients with severe exercise-induced myolysis. British Journal of Anaesthesia 66(1): 138-140, 1991

The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. Journal of Clinical Investigation 117(12): 3940-3951, 2007

Changes in ryanodine-induced contractures by stimulus frequency in malignant hyperthermia susceptible and malignant hyperthermia nonsusceptible dog skeletal muscle. Journal of Pharmacology and Experimental Therapeutics 282(3): 1331-1336, 1997

The risk of malignant tumours in First-degree relatives of men with early onset prostate cancer: A population-based cohort study. European Journal of Cancer 33(13): 2237-2240, 1997

Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity. Frontiers in Pharmacology 8: 555-555, 2017

Phenotyping malignant hyperthermia susceptibility by measuring halothane-induced changes in myoplasmic calcium concentration in cultured human skeletal muscle cells. British Journal of Anaesthesia 89(4): 571-579, 2002

A study of a family with the skeletal muscle RYR1 mutation (c.7354C>T) associated with central core myopathy and malignant hyperthermia susceptibility. Journal of Clinical Neuroscience 19(1): 65-70, 2012

In vitro muscle contractures induced by halothane and suxamethonium. II: Human skeletal muscle from normal and malignant hyperthermia susceptible patients. British Journal of Anaesthesia 58(12): 1433-1439, 1986

Association between known or strongly suspected malignant hyperthermia susceptibility and postoperative outcomes: an observational population-based study. Canadian Journal of Anaesthesia 2018, 2018

Should we use muscle biopsy to diagnose malignant hyperthermia susceptibility?. Anesthesiology 79(1): 1-4, 1993

Malignant hyperthermia susceptibility in X-linked muscle dystrophies. Pediatric Neurology 2(6): 356-358, 1986

Masseter muscle rigidity and malignant hyperthermia susceptibility. Anesthesia & Analgesia 65(2): 161-164, 1986

Statin Use and Self-Reported Hindering Muscle Complaints in Older Persons: A Population Based Study. Plos One 11(12): E0166857, 2017

Clinical and muscle biopsy findings in malignant hyperthermia susceptibility. Acta Neurologica Scandinavica 74(6): 452-459, 1986

Anesthesia for muscle biopsy to test for susceptibility to malignant hyperthermia. Revista Brasileira de Anestesiologia 2019, 2019